Analysts expect DaVita HealthCare Partners Inc. (NYSE:DVA) to announce $0.94 earnings per share for the current quarter, according to Zacks. Five analysts have issued estimates for DaVita HealthCare Partners’ earnings, with the highest EPS estimate coming in at $0.97 and the lowest estimate coming in at $0.90. DaVita HealthCare Partners posted earnings of $0.95 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 1.1%. The company is scheduled to issue its next earnings report on Wednesday, November 1st.
According to Zacks, analysts expect that DaVita HealthCare Partners will report full-year earnings of $3.54 per share for the current financial year, with EPS estimates ranging from $3.34 to $3.63. For the next fiscal year, analysts expect that the company will report earnings of $3.81 per share, with EPS estimates ranging from $3.53 to $3.96. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover DaVita HealthCare Partners.
DaVita HealthCare Partners (NYSE:DVA) last posted its quarterly earnings results on Tuesday, August 1st. The company reported $0.92 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.90 by $0.02. DaVita HealthCare Partners had a net margin of 8.68% and a return on equity of 14.02%. The firm had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same quarter last year, the firm posted $1.01 earnings per share. DaVita HealthCare Partners’s revenue for the quarter was up 4.3% compared to the same quarter last year.
A number of brokerages have recently commented on DVA. BidaskClub lowered DaVita HealthCare Partners from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. Jefferies Group LLC lowered DaVita HealthCare Partners from a “buy” rating to a “hold” rating and upped their price target for the stock from $64.89 to $70.00 in a report on Monday, June 26th. Zacks Investment Research lowered DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Goldman Sachs Group, Inc. (The) reiterated a “sell” rating and set a $62.00 price target on shares of DaVita HealthCare Partners in a report on Thursday, May 25th. Finally, Royal Bank Of Canada reiterated a “hold” rating and set a $64.00 price target on shares of DaVita HealthCare Partners in a report on Wednesday, September 6th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $68.88.
DaVita HealthCare Partners (NYSE:DVA) traded up 0.82% on Tuesday, reaching $60.29. 1,911,642 shares of the company traded hands. The firm has a 50 day moving average price of $58.84 and a 200 day moving average price of $64.53. The stock has a market capitalization of $11.53 billion, a price-to-earnings ratio of 9.18 and a beta of 0.91. DaVita HealthCare Partners has a 52-week low of $54.50 and a 52-week high of $70.16.
A number of large investors have recently made changes to their positions in DVA. BlackRock Inc. grew its position in DaVita HealthCare Partners by 2,315.8% in the first quarter. BlackRock Inc. now owns 12,892,477 shares of the company’s stock valued at $876,303,000 after acquiring an additional 12,358,806 shares during the period. Park West Asset Management LLC grew its position in DaVita HealthCare Partners by 88.8% in the first quarter. Park West Asset Management LLC now owns 1,856,516 shares of the company’s stock valued at $126,187,000 after acquiring an additional 873,064 shares during the period. Tudor Investment Corp ET AL bought a new stake in DaVita HealthCare Partners in the first quarter valued at $31,376,000. PGGM Investments bought a new stake in DaVita HealthCare Partners in the second quarter valued at $28,598,000. Finally, FIL Ltd grew its position in DaVita HealthCare Partners by 82.0% in the first quarter. FIL Ltd now owns 820,581 shares of the company’s stock valued at $55,775,000 after acquiring an additional 369,784 shares during the period. Hedge funds and other institutional investors own 83.43% of the company’s stock.
DaVita HealthCare Partners Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.